Molecular structure of LY2606368, CAS Number: 1234015-52-1
LY2606368 (CAS 1234015-52-1)
CAS Number:
1234015-52-1
Molecular Weight:
365.4
Molecular Formula:
C18H19N7O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY2606368 (CAS 1234015-52-1) References
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. | Hong, D., et al. 2016. J Clin Oncol. 34: 1764-71. PMID: 27044938
- CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. | Manic, G., et al. 2018. Gut. 67: 903-917. PMID: 28389531
- Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. | Heidler, CL., et al. 2020. Int J Cancer. 147: 1059-1070. PMID: 31782150
- Disposition of [14C]LY2606368 following intravenous administration in patients with advanced and/or metastatic solid tumours. | Wickremsinhe, ER., et al. 2020. Xenobiotica. 50: 793-804. PMID: 31847673
- A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. | Gatti-Mays, ME., et al. 2020. Oncologist. 25: 1013-e1824. PMID: 32510664
- Comparative Activity and Off-Target Effects in Cells of the CHK1 Inhibitors MK-8776, SRA737, and LY2606368. | Ditano, JP. and Eastman, A. 2021. ACS Pharmacol Transl Sci. 4: 730-743. PMID: 33860197
- A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). | Cash, T., et al. 2021. Pediatr Blood Cancer. 68: e29065. PMID: 33881209
- A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. | Byers, LA., et al. 2021. Clin Lung Cancer. 22: 531-540. PMID: 34034991
- A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. | Konstantinopoulos, PA., et al. 2022. Gynecol Oncol. 167: 213-225. PMID: 36192237
- Immune perturbation network identifies an EMT subtype with chromosomal instability and tumor immune-desert microenvironment. | Xu, H., et al. 2023. iScience. 26: 107871. PMID: 37766999
Inhibitor of:
4931417G12Rik, BC066135, BRCA1, C10orf6, CCDC57, Chk1, MYT1L, PAR-3, Rad17, Rad3, RIA1, VSIG (V-set and immunoglobulin domain containing), and Wee 1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY2606368, 5 mg | sc-507521 | 5 mg | $176.00 | |||
LY2606368, 10 mg | sc-507521A | 10 mg | $300.00 | |||
LY2606368, 25 mg | sc-507521B | 25 mg | $500.00 | |||
LY2606368, 100 mg | sc-507521C | 100 mg | $1900.00 | |||
LY2606368, 1 g | sc-507521D | 1 g | $8000.00 | |||
LY2606368, 10 g | sc-507521E | 10 g | $25000.00 |